AR and prostate cancer: Another study in a patient-derived xenograft model of castration-resistant prostate cancer also demonstrated that high BIRC6 protein levels were associated with resistance to the androgen receptor inhibitor enzalutamide and that targeting BIRC6 inhibited cancer growth both in vitro and in vivo.